[1] Clavel F, Hance AJ. HIV drug resistance[J].N Engl J Med, 2004, 350: 1023-1035. [2] Jamjoom GA. Protease inhibitors as potential therapeutic agents for AIDS[J].Ann Saudi Med,1991,11(5): 568-575. [3] Lavalle C,Peña F,Madrazo M, et al. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with aids treated with protease inhibitors[J].Arch Med Res,2000,31(5): 515-519. [4] Perry CM, Noble S. Saquinavir soft-gel capsule formulation: A review of its use in patients with HIV infection[J].Antimicrob Agents Chemother,1998,55(3): 461-486. [5] Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease[J].Antimicrob Agents Chemother, 1998,42(12):3218-3224. [6] Monini P, Sgadari P, Barillari G,et al. HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity[J]. Antimicrob Chemother,2003,51(2): 207-211. [7] 邓万俊. HIV蛋白酶抑制剂的药物相互作用研究进展[J]. 国外医药抗生素分册,2006, 27(1): 9-15. [8] Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections[J]. N Engl J Med, 2001,344(13): 984-996. [9] Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir[J].Br J Clin Pharmacol,1997,44(2): 190-194. [10] Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir[J]. Drug Metab Dispos, 2011,39(6):1070-1078. [11] Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection[J].Clin Pharmacokinet,1999,36(4): 289-304. [12] Waxman D. Steroid hormones and other physiologic regulators of livercytochromes P450: metabolic reactions and regulatory pathways[J].Adv Mol Cell Biol,1996,14: 341-374. [13] Shibata N, Matsumura Y, Okamoto H, et al. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors[J].J Pharm Pharmacol,2000,52(10): 1239-1246. [14] Shibata N, Gao W, Okamoto H, et al. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats[J].J Pharm Pharmacol,2002,54(2): 221-229. [15] Chiba M, Jin L, Neway W, et al.P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra[J].Drug Metab Dispos,2001,29(1): 1-3. [16] Jayakanthan M, Chandrasekar S, Muthukumaran J, et al. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS[J]. J Mol Graph Model,2009,28(5): 455-463. [17] Granfors MT, Wang JS, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro[J].Basic Clin Pharmacol Toxicol,2006,98(1): 79-85. [18] Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5[J].Clin Pharmacol Ther, 2005,78(6): 605-618. [19] Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir[J].Clin Pharmacol Ther,2007,81(5):708-712. [20] Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART[J].Eur J Clin Pharmacol, 2009, 65(7):667-678. [21] Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir[J].Clin Pharmacol Ther, 2010,87(6): 735-742. [22] Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions[J].Drug Metab Dispos,2007,35(10): 1853-1859. [23] Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir[J]. Drug Metab Dispos,2011,39(12):2329-2337. [24] Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction[J].Drug Metab Dispos,1999,27(8): 902-908. [25] Ikezoe T,Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo[J].Cancer Res,2004,64(20): 7426-7431. [26] Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma[J].Clin Lymphoma Myeloma Leuk,2010,10(2): E22-25. [27] Cingolani A,Torti L, Pinnetti C,et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma[J].AIDS,2010,24(15): 2408-2412. [28] Berbel Garcia A, Latorre Ibarra A, Porta Etessam J,et al. Protease inhibitor-induced carbamazepine toxicity[J].Clin Neuropharmacol,2000,23(4): 216-218. [29] Palkama VJ, Ahonen J, Neuvonen PJ, et al. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam[J].Clin Pharm Ther,1999,66(1): 33-39. [30] Burger DM,Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir[J].AIDS,1998,12(15): 2080-2082. [31] Goshman L, Fish J, Rolle K. Clinically significant cytochrome P450 drug interaction[J].J Pharm Society of Wisconsin, 1999,26(5/6): 23-38. [32] Wensing AM,van Maarseveen NM,Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance[J]. Antiviral Res,2010, 85(1): 59-74. [33] Shelton MJ, Cloen D, Becker M,et al. Evaluation of the pharmacokinetic interaction between phenytoin and nelfinavir in healthy volunteers at steady state[C]. In: Pro-gram and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000. [34] Flexner C. HIV-protease inhibitors[J].N Engl J Med,1998,338: 1281-1293. [35] Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents[J]. Ann Pharmacother, 2002,36(10):1598-1613. [36] Curran A, Ribera E. HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin[J]. Expert Rev Anti Infect Ther, 2011,9(12):1115-1118. [37] Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors[J].Drug Saf,1999,20(2): 147-169. [38] Peytavin G, Gautran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers[J].Eur J Clin Pharmacol,2005,61(4): 267-273. [39] Kupferschmidt HH,Fattinger KE, Ha HR,et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man[J].Br J Clin Pharmacol,1998,45(4): 355-359. [40] Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes[J].Br J Clin Pharmacol,2002,54(4): 349-356. [41] Gutmann H, Fricker G, Drewe J, et al.Interactions of HIV protease inhibitors with ATP-dependent drug export proteins[J].Mol Pharmacol,1999,56(2): 383-389. [42] Williams GC. Oral absorption of the HIV protease inhibitors: a current update[J].Adv Drug Deliv,1999, 39(1/2/3): 211-238. [43] Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter[J]. Annu Rev Biochem, 1993,62: 385-427. [44] Solon EG, Balani SK, Luo G, et al. Interaction of ritonavir on tissue distribution of a [(14)c] L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography[J].Drug Metab Dispos,2002,30(11): 1164-1169. [45] Drewe J, Gutmann H, Fricker G, et al.HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833[J].Biochem Pharmacol,1999, 57(10): 1147-1152. [46] Shaik N, Pan G, Elmquist WF, et al. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors[J].J Pharm Sci,2008,97(12): 5421-5433. [47] Kaddoumi A, Choi SU, Kinman L, et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid[J].Drug Metab Dispos,2007, 35(9):1459-1462. [48] Storch CH, Theile D, Lindenmaier H,et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein[J].Biochem Pharmacol,2007,73(10): 1573-1581. [49] Haas DW, Wu HL, Bosch RJ,et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study[J].J Acquir Immune Defic Syndr, 2003,34(3): 295-298. [50] Lucia MB, Rutella S, Leone G, et al. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART[J].J Acquir Immune Defic Syndr,2001,27(4): 321-230. [51] Pal D, Mitra AK.MDR- and CYP3A4-mediated drug-herbal interactions[J].Life Sci,2006,78(18): 2131-2145. [52] Berginc K, Trdan T, Trontelj J,et al. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy[J].Biopharm Drug Dispos, 2010,31(8/9):495-505. [53] Patel J, Buddha B, Dey S,et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity[J]. Am J Ther,2004, 11(4): 262-77. [54] Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins[J].J Acquir Immune Defic Syndr, 2004, 36(2):649-658. [55] Bousquet L, Roucairol C, Hembury A,et al. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier[J].AIDS Res Hum Retroviruses, 2008, 24(9):1147-1154. [56] Zastre JA, Chan GN, Ronaldson PT, et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line[J].J Neurosci Res,2009, 87(4):1023-1036. [57] Sánchez Mdel C, López P, Vélez R, et al. P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors[J].Ethn Dis,2008,18(2 Suppl 2): S2-60-4. [58] Kaddoumi A, Choi SU, Whittington D, et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid[J].Drug Metab Dispos,2007, 35(9):1459-1462. [59] Janneh O, Jones E, Chandler B, et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes[J].J Antimicrob Chemother,2007, 60(5):987-993. [60] Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells[J].J Acquir Immune Defic Syndr Hum Retrovirol,1998,19(3): 203-209. [61] Ye ZW, Camus S, Augustijns P, et al. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes[J].Biopharm Drug Dispos,2010,31(2/3): 178-188. [62] Janneh O, Anwar T, Jungbauer C, et al. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir[J].Antivir Ther,2009,14(7):965-974. [63] Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices[J].Drug Metab Pharmacokinet,2010,25(3): 307-313. [64] Gupta A, Zhang Y, Unadkat JD, et al. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2) [J].J Pharmacol Exp Ther, 2004,310(1):334-341. [65] Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver[J]. Gastroenterology, 2001,120(2): 525-533. [66] Ye ZW, Van Pelt J, Camus S, et al. Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes[J].J Pharm Sci,2010,99(6): 2886-2898. [67] Annaert P, Augustijns P, Stieger B, et al. Interaction of HIV protease inhibitors with OATP1B1, 1B3 and 2B1[J]. Xenobiotica,2010,40(3): 163-176. [68] Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations[J].Clin Pharmcokinet,1997,32(3):194-209. [69] Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents[J].Clin Pharmacokinet,2008,47(2): 75-89. [70] Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report[J].Liver Transpl,2002,8(9):838-840. [71] Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors[J].Clin Infect Dis,2004,38 Suppl 2: S90-S97. [72] 郑青山,孙瑞元. 药物相互作用动力学分析方法及其CoDrug软件[J]. 中国临床药理学与治疗学, 2002, 7 (1) :81-85. |